- GLP-1 receptor agonists can lead to significant weight loss of 15-20% of body weight for many patients.
- A surge in prescriptions has raised concerns about long-term sustainability and nutritional safety.
- Medication alone is not a cure for obesity, and patients risk muscle loss and nutrient deficiencies without nutritional support.
- Dietitians must be central to treatment teams to ensure safe and effective outcomes.
- A multidisciplinary care approach is crucial to prevent risks associated with GLP-1 drugs, such as sarcopenia and disordered eating patterns.
Obesity affects over 650 million adults worldwide, contributing to more than 5 million deaths annually, according to the World Health Organization. With the advent of highly effective GLP-1 receptor agonists like semaglutide and tirzepatide, weight loss of 15% to 20% of body weight is now achievable for many patients. However, a surge in prescriptions—up 60% globally since 2022—has raised concerns about long-term sustainability and nutritional safety. Now, a landmark consensus statement from leading obesity and dietetic societies warns that medication alone is not a cure, and without structured nutritional support, patients risk muscle loss, nutrient deficiencies, and weight regain. The guidance, backed by 26 international experts, stresses that dietitians must be central to treatment teams to ensure safe, effective, and durable outcomes.
\n
Why Multidisciplinary Care Matters Now
\n
The release of the new consensus at the European Congress on Obesity (ECO 2026) in Istanbul marks a pivotal shift in how obesity is clinically managed. While GLP-1 drugs have revolutionized treatment, their widespread use—fueled by media attention and direct-to-consumer marketing—has outpaced clinical infrastructure. Many patients are initiating therapy without nutritional assessment or follow-up, increasing risks of sarcopenia, micronutrient deficiencies, and disordered eating patterns. The consensus, co-authored by Dr. Laurence Dobbie of King’s College London, underscores that obesity is a chronic, relapsing disease requiring comprehensive care. It calls for a redefinition of treatment standards, positioning registered dietitians as essential providers alongside physicians, endocrinologists, and mental health professionals. Without this integration, the authors argue, the gains from pharmacotherapy may be short-lived or harmful.
\n
New Consensus Unites Global Experts
\n
The guidance was developed by a coalition including the European Association for the Study of Obesity (EASO), the Academy of Nutrition and Dietetics, and the Obesity Medicine Association, drawing on evidence from over 120 clinical trials and real-world studies. It outlines a framework for dietitian-led care before, during, and after GLP-1 therapy, with specific protocols for protein intake, micronutrient monitoring, and behavioral support. The panel, composed of 26 experts from 14 countries, reached agreement on 28 key recommendations, including mandatory nutritional screening prior to drug initiation and regular dietitian consultations throughout treatment. The consensus also addresses disparities in access, noting that low-income and rural populations often lack access to both medications and qualified nutrition professionals, exacerbating health inequities. The framework is designed to be adaptable across healthcare systems, from primary care clinics to specialized obesity centers.
\n
Science Behind the Shift
\n
GLP-1 drugs work by mimicking a gut hormone that regulates appetite and insulin secretion, leading to reduced caloric intake and improved glycemic control. However, their mechanism—prolonged satiety and delayed gastric emptying—can inadvertently reduce protein consumption and impair absorption of key nutrients like vitamin B12, iron, and calcium. Studies show that up to 30% of patients on long-term GLP-1 therapy experience significant muscle mass loss, which undermines metabolic health and increases frailty risk. Expert analysis in the consensus highlights that high-quality protein intake (1.2–1.6 g/kg/day) and resistance training are critical to preserving lean mass. Dietitians are uniquely trained to assess individual needs, design tailored meal plans, and monitor for red flags such as rapid weight loss or eating disturbances. The World Health Organization has long advocated for holistic obesity management, and this consensus aligns with that vision by embedding nutrition expertise into pharmacological care.
\n
Patient and System Implications
\n
The new guidelines have far-reaching implications for patients, clinicians, and health systems. For individuals with obesity, integrating dietitians into treatment can improve outcomes, reduce complications, and support long-term weight maintenance. For healthcare providers, the consensus sets a clear standard: prescribing GLP-1 drugs without nutritional support is no longer considered best practice. Health systems, particularly in publicly funded countries, now face pressure to expand access to dietetic services, which are currently under-resourced in many regions. Insurers may also need to revise coverage policies to include routine dietitian visits as part of obesity treatment. Without systemic changes, the authors warn, the promise of GLP-1 drugs could be undermined by preventable adverse effects and high relapse rates after discontinuation.
\n
Expert Perspectives
\n
Experts are divided on implementation but united on principle. Dr. Dobbie emphasizes that “medication can open the door, but nutrition sustains the change.” Others caution that while the science is sound, scaling dietitian-led care will require significant investment. Some clinicians worry about workforce shortages, noting that many countries have fewer than two dietitians per 10,000 people. Conversely, patient advocacy groups welcome the focus on holistic care, arguing that obesity treatment has long been reduced to quick fixes. A 2023 review in Nature Reviews Endocrinology supports the consensus, stating that “sustainable weight loss requires more than pharmacology—it demands behavioral and environmental support.”
\n
Looking ahead, the success of this model will depend on policy adoption, workforce development, and patient education. Researchers are already studying the cost-effectiveness of integrating dietitians into obesity care pathways. As GLP-1 drugs evolve—next-generation compounds may offer even greater efficacy—the need for expert nutritional oversight will only grow. The central question remains: can health systems adapt quickly enough to ensure that innovation translates into equitable, lasting benefits for all people with obesity?
Source: MedicalXpress